



Valeant Pharmaceuticals North America LLC
400 Somerset Corporate Blvd., Bridgewater, NJ 08807
Tel: 908-927-1400
www.valeant.com

June 21, 2016

Notice to 340B Covered Entities regarding an overcharge that may have occurred for 3 new NDCs introduced and the issuance of credit.

Dear 340B Covered Entities:

Valeant Pharmaceuticals, Inc. identified a delay in communicating the 340B ceiling price for 3 NDC changes that were newly introduced August 4, 2015 and were not added to the Valeant 340B contract until September 8, 2015. 340B covered entities that purchased the NDCs below during this timeframe and were not charged the 340B ceiling price will receive a credit to be processed through the Wholesaler from which they purchased these products from. Please send an e-mail to paula.martins@valeant.com so that we can work with you to insure a credit/rebill is processed for any overcharged units.

NDC	DESCRIPTION
00187-4330-05	Isuprel (Isoproterenol HCL INJ USP) 5ml AMP Pack of 10
00187-4330-01	Isuprel (Isoproterenol HCL INJ USP) .2mg/ml 1ml AMP
00187-4302-02	Nitropress (Sodium Nitroprusside Injection) 50mg/2ml

Thank you in advance for your cooperation as we work to ensure that all of customer receives the proper contract pricing.

Kind Regards,

Paula Martins
Director, Government Pricing
paula.martins@valeant.com
(908) 927- 0802 office

CC. Valued Wholesalers Customers